Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease

Gut

Volumn 66, Issue 1, 2017, Pages 180-190

  Rotman, Yaron ^a   Sanyal, Arun J ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMLEXANOX; ARAMCHOL; CENICRIVIROC; ELAFIBRANOR; EMRICASAN; ENZYME INHIBITOR; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; GR MD 02; IMM 124E; IMMUNOGLOBULIN G; LIRAGLUTIDE; NDI 010976; OBETICHOLIC ACID; PENTOXIFYLLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PLACEBO; PROTEIN INHIBITOR; SAROGLITAZAR; SELONSERTIB; SIMTUZUMAB; SOLITHROMYCIN; TESAMORELIN; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLIXIBAT; ANTIOBESITY AGENT; ANTIOXIDANT; CELL RECEPTOR; CHENODEOXYCHOLIC ACID; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FARNESOID X-ACTIVATED RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOLOGIC FACTOR; INCRETIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ARTICLE; DRUG DOSE COMPARISON; DRUG TARGETING; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; IMMUNOMODULATION; INFLAMMATION; LIFESTYLE MODIFICATION; LIPOGENESIS; METABOLIC STRESS; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); WEIGHT REDUCTION; AGONISTS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG REPOSITIONING; MOLECULARLY TARGETED THERAPY; NON-ALCOHOLIC FATTY LIVER DISEASE;

ANTI-OBESITY AGENTS; ANTIOXIDANTS; CHENODEOXYCHOLIC ACID; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG DISCOVERY; DRUG REPOSITIONING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOLOGIC FACTORS; INCRETINS; LIPOGENESIS; MOLECULAR TARGETED THERAPY; NON-ALCOHOLIC FATTY LIVER DISEASE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84988462353     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2016-312431     Document Type: Article

References (131)

1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-95.
2. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-Aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140:124-31.
3. Wong VW, Chu WC, Wong GL, et al. Prevalence of non-Alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012;61:409-15.
4. Kanwal F, Kramer JR, Duan Z, et al. Trends in the burden of nonalcoholic fatty liver disease in a United States cohort of veterans. Clin Gastroenterol Hepatol 2016;14:301-8.e1-2.
5. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011;9:524-30.e1; quiz e60.
6. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
7. Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547-54.
8. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-92.
9. Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343-51.
10. Lambert JE, Ramos-Roman MA, Browning JD, et al. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2014;146:726-35.
11. Fabbrini E, Mohammed BS, Magkos F, et al. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 2008;134:424-31.
12. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010;51:679-89.
13. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010;52:774-88.
14. Poulsen L, Siersbaek M, Mandrup S. PPARs: fatty acid sensors controlling metabolism. Semin Cell Dev Biol 2012;23:631-9.
15. Brown JD, Plutzky J. Peroxisome proliferator-Activated receptors as transcriptional nodal points and therapeutic targets. Circulation 2007;115:518-33.
16. Kersten S, Seydoux J, Peters JM, et al. Peroxisome proliferator-Activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 1999;103:1489-98.
17. Montagner A, Polizzi A, Fouché E, et al. Liver PPARa is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. Gut 2016;65:1202-14.
18. Musso G, Gambino R, Cassader M, et al. A meta-Analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010;52:79-104.
19. Bojic LA, Huff MW. Peroxisome proliferator-Activated receptor d: a multifaceted metabolic player. Curr Opin Lipidol 2013;24:171-7.
20. Bojic LA, Burke AC, Chhoker SS, et al. Peroxisome proliferator-Activated receptor d agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 2014;34:52-60.
21. Risérus U, Sprecher D, Johnson T, et al. Activation of peroxisome proliferator-Activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 2008;57:332-9.
22. Staels B, Rubenstrunk A, Noel B, et al. Hepatoprotective effects of the dual peroxisome proliferator-Activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 2013;58:1941-52.
23. Hanf R, Millatt LJ, Cariou B, et al. The dual peroxisome proliferator-Activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-Activated receptor gamma-Associated adverse cardiac effects. Diab Vasc Dis Res 2014;11:440-7.
24. Cariou B, Hanf R, Lambert-Porcheron S, et al. Dual peroxisome proliferator-Activated receptor a/d agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care 2013;36:2923-30.
25. Ratziu V, Harrison S, Francque S, et al. Elafibranor, an agonist of the peroxisome proliferator-Activated receptor-A and-d, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 2016;150:1147-59. e5.
26. Sanyal AJ, Friedman SL, McCullough AJ, et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U. S. Food and Drug Administration Joint Workshop. Hepatology 2015;61:1392-405.
27. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
28. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-307.
29. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39:188-96.
30. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-85.
31. Rinella ME, Lominadze Z, Loomba R, et al. Practice patterns in NAFLD and NASH: real life differs from published guidelines. Therap Adv Gastroenterol 2016;9:4-12.
32. Pai V, Paneerselvam A, Mukhopadhyay S, et al. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared to Pioglitazone 45 mg in diabetic dyslipidemia (PRESS V). J Diabetes Sci Technol 2014;8:132-41.
33. Jani RH, Pai V, Jha P, et al. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes Technol Ther 2014;16:63-71.
34. Jain MR, Giri SR, Bhoi B, et al. Saroglitazar shows therapeutic benefits in mouse model of nonalcoholic fatty liver disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). Diabetes 2015;64:A503-A.
35. Saboo BD, Prajapati A, Joshi S, et al. To Assess the Effect of 4 mg Saroglitazar on patients of diabetes dyslipidemia with nonalcoholic fatty liver disease for 24 weeks at diabetes care centre. Diabetes 2015;64:A180-A.
36. Giri S, Bhoi B, Trivedi C, et al. Efficacy of Saroglitazar, a Novel PPARa/? Agonist in a Mouse Model of Non-Alcoholic Steatohepatitis. Keystone Symposium-Liver Metabolism and Nonalcoholic Fatty Liver Disease (NAFLD). Whistler, BC, Canada, 2015.
37. Chen Z, Vigueira PA, Chambers KT, et al. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-Activated receptor ?-sparing thiazolidinedione. J Biol Chem 2012;287:23537-48.
38. Colca JR, McDonald WG, Cavey GS, et al. Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)-relationship to newly identified mitochondrial pyruvate carrier proteins. PloS ONE 2013;8:e61551.
39. Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004;113:1408-18.
40. Porez G, Prawitt J, Gross B, et al. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res 2012;53:1723-37.
41. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-Alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015;385:956-65.
42. Gege C, Kinzel O, Steeneck C, et al. Knocking on FXR's door: the "hammerhead"-structure series of FXR agonists-Amphiphilic isoxazoles with potent in vitro and in vivo activities. Curr Top Med Chem 2014;14:2143-58.
43. McMahan RH, Wang XX, Cheng LL, et al. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J Biol Chem 2013;288:11761-70.
44. Ratziu V. Treatment of NASH with ursodeoxycholic acid: pro. Clin Res Hepatol Gastroenterol 2012;36(Suppl 1):S41-5.
45. Liechti F, Dufour JF. Treatment of NASH with ursodeoxycholic acid: cons. Clin Res Hepatol Gastroenterol 2012;36(Suppl 1):S46-52.
46. Mueller M, Thorell A, Claudel T, et al. Ursodeoxycholic acid exerts farnesoid X receptor-Antagonistic effects on bile acid and lipid metabolism in morbid obesity. J Hepatol 2015;62:1398-404.
47. Le TA, Chen J, Changchien C, et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012;56:922-32.
48. Herrema H, Meissner M, van Dijk TH, et al. Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor-And liver X receptor alpha-controlled metabolic pathways in mice. Hepatology 2010;51:806-16.
49. Braunlin W, Zhorov E, Guo A, et al. Bile acid binding to sevelamer HCl. Kidney Int 2002;62:611-19.
50. McGettigan B, McMahan R, Porsche C, et al. Sevelamer improves hepatic steatosis and modulates inflammation in a Western Diet mouse model of non-Alcoholic fatty liver disease (NAFLD). Hepatology 2014;60:746A-7A.
51. Luo Y, Wang XX, Orlicky DJ, et al. Bile Acid Sequestrant Prevents NAFLD/NASH in Diet Induced Obesity and Insulin Resistant Mice. Keystone Symposium-Liver Metabolism and Nonalcoholic Fatty Liver Disease (NAFLD). Whistler, BC, Canada, 2015.
52. Chen L, Yao X, Young A, et al. Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. Am J Physiol Endocrinol Metab 2012;302:E68-76.
53. Leikin-Frenkel A, Gonen A, Shaish A, et al. Fatty acid bile acid conjugate inhibits hepatic stearoyl coenzyme A desaturase and is non-Atherogenic. Arch Med Res 2010;41:397-404.
54. Leikin-Frenkel A, Goldiner I, Leikin-Gobbi D, et al. Treatment of preestablished diet-induced fatty liver by oral fatty acid-bile acid conjugates in rodents. Eur J Gastroenterol Hepatol 2008;20:1205-13.
55. Safadi R, Konikoff FM, Mahamid M, et al. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:2085-91.e1.
56. Foster DW. Malonyl-CoA: the regulator of fatty acid synthesis and oxidation. J Clin Invest 2012;122:1958-9.
57. Westlin WF, Blanchette H, Harriman G, et al. NDI-010976, a potent, liver-directed, oral inhibitor of acetyl coa carboxylase for non-Alcoholic steatohepatitis: pharmacodynamic effects on hepatic de novo lipogenesis in obese but otherwise healthy adult male volunteers. J Hepatol 2016;64:S190-S1.
58. Ren S, Ning Y. Sulfation of 25-hydroxycholesterol regulates lipid metabolism, inflammatory responses, and cell proliferation. Am J Physiol Endocrinol Metab 2014;306:E123-30.
59. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-39.
60. Abu-Hamdah R, Rabiee A, Meneilly GS, et al. Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 2009;94:1843-52.
61. Armstrong MJ, Houlihan DD, Rowe IA, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-Analysis of the LEAD program. Aliment Pharmacol Ther 2013;37:234-42.
62. Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007;29:139-53.
63. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-Alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016;387:679-90.
64. Armstrong MJ, Hull D, Guo K, et al. Glucagon-like peptide 1 decreases lipotoxicity in non-Alcoholic steatohepatitis. J Hepatol 2016;64:399-408.
65. Yilmaz Y, Yonal O, Deyneli O, et al. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol Belg 2012;75:240-4.
66. Kato H, Nagai Y, Ohta A, et al. Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes. Diabetes Res Clin Pract 2015;109:199-205.
67. Dohil R, Schmeltzer S, Cabrera BL, et al. Enteric-coated cysteamine for the treatment of paediatric non-Alcoholic fatty liver disease. Aliment Pharmacol Ther 2011;33:1036-44.
68. Fukuhara T, Hyogo H, Ochi H, et al. Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. Hepatogastroenterology 2014;61:323-8.
69. Cui JY, Philo L, Nguyen P, et al. Sitagliptin versus placebo in the treatment of non-Alcoholic fatty liver disease: a randomized controlled trial. J Hepatol 2016;64: S192-3.
70. Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007;46:1081-90.
71. Farrell GC, van Rooyen D. Liver cholesterol: is it playing possum in NASH? Am J Physiol Gastrointest Liver Physiol 2012;303:G9-11.
72. Pastori D, Polimeni L, Baratta F, et al. The efficacy and safety of statins for the treatment of non-Alcoholic fatty liver disease. Dig Liver Dis 2015;47:4-11.
73. Dongiovanni P, Petta S, Mannisto V, et al. Statin use and non-Alcoholic steatohepatitis in at risk individuals. J Hepatol 2015;63:705-12.
74. Blais P, Lin M, Kramer JR, et al. Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia. Dig Dis Sci 2016;61:1714-20.
75. Kargiotis K, Athyros VG, Giouleme O, et al. Resolution of non-Alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol 2015;21:7860-8.
76. Loomba R, Sirlin CB, Ang B, et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology 2015;61:1239-50.
77. Nies VJ, Sancar G, Liu W, et al. Fibroblast growth factor signaling in metabolic regulation. Front Endocrinol (Lausanne) 2015;6:193.
78. Mu J, Pinkstaff J, Li Z, et al. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes 2012;61:505-12.
79. Wu X, Ge H, Lemon B, et al. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem 2010;285:5165-70.
80. Luo J, Ko B, To C, et al. Treatment with Ngm282 Significantly improves liver histopathology in a mouse model of non-Alcoholic steatohepatitis (Nash). Journal of Hepatology 2015;62:S694-S.
81. Cable EE, Finn PD, Stebbins JW, et al. Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. Hepatology 2009;49:407-17.
82. Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA 2014;312:380-9.
83. Nishizawa H, Iguchi G, Murawaki A, et al. Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy. Eur J Endocrinol 2012;167:67-74.
84. Trajkovski M, Hausser J, Soutschek J, et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 2011;474:649-53.
85. Xu Q, Li Y, Shang YF, et al. miRNA-103: molecular link between insulin resistance and nonalcoholic fatty liver disease. World J Gastroenterol 2015;21:511-16.
86. Kowdley KV, Wilson LA, Van Natta ML, et al. Efficacy and Safety of Vitamin E in Nonalcoholic Steatohepatitis Patients With and Without diabetes: Pooled analysis from the PIVENS and FLINT NIDDK NASH CRN Trials. Hepatology 2015;62:264A-A.
87. Kaempf-Rotzoll DE, Traber MG, Arai H. Vitamin E and transfer proteins. Curr Opin Lipidol 2003;14:249-54.
88. Miller ER III, Pastor-Barriuso R, Dalal D, et al. Meta-Analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37-46.
89. Abner EL, Schmitt FA, Mendiondo MS, et al. Vitamin E and all-cause mortality: a meta-Analysis. Curr Aging Sci 2011;4:158-70.
90. Schürks M, Glynn RJ, Rist PM, et al. Effects of vitamin E on stroke subtypes: meta-Analysis of randomised controlled trials. BMJ 2010;341:c5702.
91. Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011;306:1549-56.
92. Schwimmer JB, Lavine JE, Neuschwander-Tetri BA, et al. Cysteamine Bitartrate Delayed-Release (DR) for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Children (CyNCh) Trial. Hepatology 2015;62:1398A-9A.
93. Syn WK, Choi SS, Diehl AM. Apoptosis and cytokines in non-Alcoholic steatohepatitis. Clin Liver Dis 2009;13:565-80.
94. Feldstein AE, Gores GJ. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci 2005;10:3093-9.
95. Linton SD, Aja T, Armstrong RA, et al. First-in-class pan caspase inhibitor developed for the treatment of liver disease. J Med Chem 2005;48:6779-82.
96. Pockros PJ, Schiff ER, Shiffman ML, et al. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology 2007;46:324-9.
97. Shiffman ML, Pockros P, McHutchison JG, et al. Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor-A randomized placebo-controlled study in patients with chronic hepatitis C. Aliment Pharmacol Ther 2010;31:969-78.
98. Barreyro FJ, Holod S, Finocchietto PV, et al. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-Alcoholic steatohepatitis. Liver Int 2015;35:953-66.
99. Shiffman M, Freilich B, Vuppalanchi R, et al. A Placebo-controlled, multicenter, double-blind, randomised trial of emricasan in subjects with non-Alcoholic fatty liver disease (Nafld) and raised transaminases. J Hepatology 2015;62:S282-S.
100. Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:1637-48.
101. Thursz MR, Richardson P, Allison M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 2015;372:1619-28.
102. Mathurin P, Louvet A, Duhamel A, et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA 2013;310:1033-41.
103. Zein CO, Yerian LM, Gogate P, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011;54:1610-19.
104. Zein CO, Lopez R, Fu X, et al. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology 2012;56:1291-9.
105. Zeng T, Zhang CL, Zhao XL, et al. Pentoxifylline for the treatment of nonalcoholic fatty liver disease: a meta-Analysis of randomized double-blind, placebo-controlled studies. Eur J Gastroenterol Hepatol 2014;26:646-53.
106. Du J, Ma YY, Yu CH, et al. Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-Analysis. World J Gastroenterol 2014;20:569-77.
107. Xiang M, Wang PX, Wang AB, et al. Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis. J Hepatol 2016;64:1365-77.
108. Budas G, Karnik S, Jonnson T, et al. Reduction of liver steatosis and fibrosis with an Ask1 inhibitor in a murine model of nash is accompanied by improvements in cholesterol, bile acid and lipid metabolism. J Hepatol 2016;64:S170.
109. Chiang SH, Bazuine M, Lumeng CN, et al. The protein kinase IKKepsilon regulates energy balance in obese mice. Cell 2009;138:961-75.
110. Reilly SM, Chiang SH, Decker SJ, et al. An inhibitor of the protein kinases TBK1 and IKK-varepsilon improves obesity-related metabolic dysfunctions in mice. Nat Med 2013;19:313-21.
111. Bertola A, Bonnafous S, Anty R, et al. Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PloS ONE 2010;5:e13577.
112. Saiman Y, Friedman SL. The role of chemokines in acute liver injury. Front Physiol 2012;3:213.
113. Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology 2014;147:577-94.e1.
114. Thompson M, Chang W, Jenkins H, et al. Improvements in APRI and FIB-4 fibrosis scores correlate with decreases in sCD14 in HIV-1 infected adults receiving cenicriviroc over 48 weeks. Hepatology 2014;60:424A-A.
115. Friedman S, Sanyal A, Goodman Z, et al. Efficacy and safety study of cenicriviroc for the treatment of non-Alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. Contemp Clin Trials 2016;47:356-65.
116. Lalor PF, Edwards S, McNab G, et al. Vascular adhesion protein-1 mediates adhesion and transmigration of lymphocytes on human hepatic endothelial cells. J Immunol 2002;169:983-92.
117. Weston CJ, Shepherd EL, Claridge LC, et al. Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. J Clin Invest 2015;125:501-20.
118. Jarolimek W, Charlton B. Phase 1 results from Pxs-4728a, a selective Ssao/Vap-1 inhibitor, for the treatment of non-Alcoholic steatohepatitis. J Hepatol 2015;62: S274-S5.
119. Nguyen V, George J. Nonalcoholic fatty liver disease management: dietary and lifestyle modifications. Semin Liver Dis 2015;35:318-37.
120. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51:121-9.
121. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-Alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23.
122. Zelber-Sagi S, Kessler A, Brazowsky E, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006;4:639-44.
123. Harrison SA, Fecht W, Brunt EM, et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 2009;49:80-6.
124. Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012;482:179-85.
125. Adar T, Ben Ya'acov A, Lalazar G, et al. Oral administration of immunoglobulin G-enhanced colostrum alleviates insulin resistance and liver injury and is associated with alterations in natural killer T cells. Clin Exp Immunol 2012;167:252-60.
126. Mizrahi M, Shabat Y, Ben Ya'acov A, et al. Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I/II clinical trial in NASH. J Inflamm Res 2012;5:141-50.
127. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012;143:913-6.e7.
128. Fernandes P, Hashiguchi T, Fujii M, et al. Anti-NASH Effects of Solithromycin in NASH-HCC Mouse Model. Gastroenterology 2014;146:S145-6.
129. Fernandes P. Mechanism of Action of the Anti-NASH effects of Solithromycin in a Predictive NASH HCC Mouse Model. Hepatology 2015;62:1301A-A.
130. Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010;16:1009-17.
131. Traber PG, Zomer E. Therapy of experimental NASH and fibrosis with galectin inhibitors. PloS ONE 2013;8:e83481.